메뉴 건너뛰기




Volumn 35, Issue 1, 2004, Pages 97-98

The Effect of Nevirapine on the Pharmacokinetics of Indinavir/Ritonavir 800/100 mg BID [1]

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INDINAVIR; NEVIRAPINE; RITONAVIR;

EID: 0347360351     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200401010-00015     Document Type: Letter
Times cited : (5)

References (6)
  • 1
    • 0035967245 scopus 로고    scopus 로고
    • Interactions among drugs for HIV and opportunistic infections
    • Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001;344:984-996.
    • (2001) N Engl J Med , vol.344 , pp. 984-996
    • Piscitelli, S.C.1    Gallicano, K.D.2
  • 2
    • 0036162141 scopus 로고    scopus 로고
    • The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers
    • Aarnoutse RE, Grintjes KJ, Telgt DS, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther. 2002;71:57-67.
    • (2002) Clin Pharmacol Ther , vol.71 , pp. 57-67
    • Aarnoutse, R.E.1    Grintjes, K.J.2    Telgt, D.S.3
  • 3
    • 0141672579 scopus 로고    scopus 로고
    • Concomitant use of non nucleoside reverse transcriptase inhibitors (NNRTI) does not decrease the inhibitory quotient of dual ritonavir/indinavir-based therapy
    • Paper presented; December 14-18; Chicago. Abstract 1728
    • Moreno A, Casado JL, Marti-Belda P, et al. Concomitant use of non nucleoside reverse transcriptase inhibitors (NNRTI) does not decrease the inhibitory quotient of dual ritonavir/indinavir-based therapy. Paper presented at: 41th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 14-18, 2001; Chicago. Abstract 1728.
    • (2001) 41th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • Moreno, A.1    Casado, J.L.2    Marti-Belda, P.3
  • 4
    • 0034458321 scopus 로고    scopus 로고
    • Pharmacodynamics of human immunodeficiency virus type I protease inhibitors
    • Acosta EP, Kakuda TN, Brundage RC, et al. Pharmacodynamics of human immunodeficiency virus type I protease inhibitors. Clin Infect Dis. 2000;30(suppl 2):S151-S159.
    • (2000) Clin Infect Dis , vol.30 , Issue.SUPPL. 2
    • Acosta, E.P.1    Kakuda, T.N.2    Brundage, R.C.3
  • 6
    • 0033844331 scopus 로고    scopus 로고
    • Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir
    • Duval X, Le MV, Longuet C, et al. Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir. Antimicrob Agents Chemother. 2000;44:2593.
    • (2000) Antimicrob Agents Chemother , vol.44 , pp. 2593
    • Duval, X.1    Le, M.V.2    Longuet, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.